EnteroTarget ApS
Nøgletal
- Afkastningsgrad
- -11,5 %
- Egenkapitalforrentning
- -11,1 %
- Likviditetsgrad
- 104,2 %
- Soliditetsgrad
- 62,9 %
Resultat
| Regnskabsperiode | |
|---|---|
Bruttoresultat | -743.935 |
Driftsresultat | -743.935 |
Skat af årets resultat | -496.519 |
Årets resultat | -451.011 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 0 |
Personaleomkostninger | 0 kr. |
Balance
| Regnskabsperiode | |
|---|---|
Likvider | 1.745.738 |
Kortfristede aktiver | 2.509.497 |
Langfristede aktiver | 3.977.748 |
Aktiver i alt | 6.487.245 |
Egenkapital | 4.079.894 |
Forpligtelser i alt | 2.407.351 |
Kortfristede forpligtelser | 2.407.350 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Andre kortfristede tilgodehavender | 6.148 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 55.548 |
Overført resultat | -3.553.655 |
Højdepunkter fra årsrapporten
Forretning og udvikling
The Company's principal activitiesThe company's principal activities consist of the development of medicinal products for the treatment of diseases of the gastrointestinal tract in humans, and activities considered by management to be related thereto.
Development in the activities and the financial situation of the CompanyThe Company's Income Statement of the financial year 1 January 2025 - 31 December 2025 shows a result of DKK -451.011 and the Balance Sheet at 31 December 2025 a balance sheet total of DKK 6.487.245 and an equity of DKK 4.079.895.
In 2025, EnteroTarget's patent application for a specialised oral capsule with active release of insulin formulations in the intestine entered the national phase in twelve jurisdictions. The accompanying international search report was positive, confirming novelty, inventive step, and industrial applicability for all patent claims.…
Expectations for the futureIn 2026, the company plans to:
1.…
Risici og væsentlige forhold
3. Uncertainties relating to going concernCommitments have been obtained from the shareholders regarding the necessary financing to meet the company's operating costs in the coming 12 months.
Post financial year eventsIn December 2025 the company initiated a capital increase of 636 new shares at a subscription price of DKK 2,414.13 per share. Prepayments representing total proceeds of DKK 1,535,387 were received before the year end. The new shares were issued in 2026.
Forpligtelser og sikkerhedsstillelser
No contingent liabilities exist at the balance sheet date.
5. Collaterals and securitiesNo securities or mortgages exist at the balance sheet date.
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger